Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis

Table 1

Characteristics of the patients.

Characteristics	Total (n = 19)
Age (years), mean (SD)	37.9 (12.0)
Sex, n (%)
Male	19 (100)
EASI, mean (SD)	36.9 (15.1)
IGA, mean (SD)	3.3 (0.5)
POEM, mean (SD)	16.6 (7.0)
DLQI, mean (SD)	12.2 (7.3)
TARC (pg/mL), mean (SD)	4,256.5 (4013.3)
Eosinophil (/µL), mean (SD)	773.9 (660.4)
LDH (IU/L), mean (SD)	323.9 (102.2)
IgE (IU/mL), mean (SD)	13,150.7 (25030.4)
Allergic comorbidity, n (%)
Rhinitis	9 (47)
Asthma	3 (16)
Conjunctivitis	2 (11)

Note. SD: standard deviation; EASI: Eczema Area and Severity Index; IGA: Investigator’s Global Assessment; POEM: Patient-Oriented Eczema Measure; DLQI: Dermatology Life Quality Index; TARC: thymus and activation-regulated chemokine.